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1. Introduction
  The goal of any drug delivery system is to provide a 
therapeutic amount of drug to the proper site in the body 
in order to promptly achieve and thereby to maintain the 
desired concentration[1]. Micro encapsulation is a process 
in which tiny particles or droplets are surrounded by 
coating to give small beads with many useful properties. 
In its simplest forms a microcapsule is a small sphere 
with a uniform wall around[2]. The material inside the 
microcapsule is referred to as the core, internal phase, or 
fill, whereas the wall is sometimes called a shell, coating 
or membrane[3]. A range of materials are suited for use as 
the capsule material: lipids, wax, crystals starch, modified 
starch, cellulose, phospholipids and other polymers. 
In general, microcapsules size ranges from 5-500毺m. 
They can be made below 1毺m and upto 5 000 毺m  in 
size. Micro-organisms offer certain advantages over 
conventional process, as microcapsules are preformed[4,5]. 
The technology is based on using yeast and other single 
micro organism as capsules to protect and deliver the active 
drug. Micro organisms were first used to encapsulate fat 
soluble materials[6]. Yeast contains very low level of fat 
(less than 10 percent) and used as micro capsules without 
lipid extending substances[7]. The technology of micro-
encapsulation using yeast cell is unique as it involves the 
use of preformed walls and membranes of micro organisms 
to provide the capsules[8,9]. This method can improve the 
shelf life and bioavailability of active ingredients. Antiviral 
drugs are a class of medication used specifically for treating 
viral infections[10]. Like antibiotics, specific antivirals are 
used for specific viruses[11]. Most of the antiviral drugs 
available are designed to deal with HIV, Herpes virus, 
which is best known for causing cold sores but actually 
covers a wide range of diseases, hepatitis B and hepatitis 
C viruses which can cause liver cancer[12,13] Acyclovir is 
an analogue of 2-deoxy guanosine that exerts its antiviral 
effects after being metabolized to acyclovir tri phosphate. 
Acyclovir triphosphate is 30-50 times as potent inhibitor of 
herpes simplex type-1 DNA polymerase[14]. Their meager 
production of acyclovir triphosphate in uninfected cells and 
its specificity for viral DNA polymerase result in minimal 
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cellular toxic effects. Acyclovir has proved effective for the 
treatment of infections caused by herpes simplex virus type 
1 and 2 and varicella-zoster virus and for suppression of 
some forms of cytomegalo virus disease. Acyclovir when 
orally administered, peak plasma concentration occurs after 
1-2 hours. It has a high distribution rate, only 30 percent 
is protein bound in plasma. The elimination half life of 
acyclovir is approximately three hours[15]. It is renally 
excreted partly by glomerlur filtration and partly by tubular 
secretion. It has not been shown to cause teratogenic and 
carcinogenic effects. Acyclovir is marketed as tablets (200 
mg, 400 mg and 800 mg) topical cream(5%), intravenous 
injection (25 mg/mL) and ophthalmic ointment(3%).
2. Materials and methods
2.1. Pre-treatment of yeast cells
  Pre-treatment of these cells was done prior to the 
encapsulation process to assess the importance of cell 
viability. A suspension of fresh yeast (100 mL of 50% solids) 
was treated overnight with sodium azide (2 g), a respiratory 
inhibitor used to prevent the cells from performing any 
energy dependant process. Sterilization by autoclaving is a 
thermally destructive process denaturing any carrier protein 
molecules likely to be involved in facilitated diffusion 
process which may be responsible for encapsulation 
process.
2.2. Preparation of acyclovir microcapsules using Baker’s 
yeast
 Acyclovir, yeast and distilled water were taken in the 
volumetric ratio of 1:2:4 respectively. This suspension was 
agitated in a magnetic stirrer for 4 hours. The suspension 
containing the cells were then centrifuged for 10 minutes at 
2 000 rpm. The supernatant solution was decanted and the 
cells were washed 5 times with deionised water and dried 
in a lyophillizer for 48 hours. 
  The effect of temperature and the drug concentration 
on microcapsule formulations were studied. The above 
procedure was followed at 4 different temperatures ( 25 ℃, 
30 ℃, 35 ℃ and 40 ℃) for 3 different doses of drug (200 mg, 
400 mg,  800 mg) (FY1-FY12).
3. Results
  The microcapsules of acyclovir was prepared using the 
drug, Baker’s yeast and water at specific ratio and various 
temperatures and lyophilized and the yield was obtained. 
The surface morphology shown by scanning electron 
microscopy (SEM) was intact and with no burst on the 
surface. The SEM of FY-3 was considered to be the best 
which was done at 10 毺m and 500 毺m (Figure 1 & 2). 
  The standard graph of the pure sample was made as per 
the procedure. The particle size analysis showed size of 
0-10 毺m in diameter was common in most groups except 
group FY-9, where most particles were found to be at 10-
20 micrometer. Particle size analysis of sample FY-8 
microcapsules by optical microscopic method was shown in 
(Figure 3, 4, 5). 
Figure 1. Morphology of FY-3(10毺m) shown by scanning 
electron microscopy.
 
Figure 2. Morphology of FY-3(500毺m) shown by scanning 
electron microscopy.
 
Figure 3. Particle size analysis of sample FY-8 microcapsules by 
optical microscopic method.
 
Figure 4. Frequency distribution curve of FY-8.
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Figure 5. Cumulative under size curve of FY-8.
  
Figure 6. Thermal analysis of standard acyclovir.
  The entrapment efficiency of the twelve samples was done 
for every 100 mg of the sample. FY-1 showed the least 
entrapment efficiency of 90.35 mg and FY-8 showed the 
most (97.61 mg) (Table 1). According to the amount of drug 
released from these samples (Table 1) it was shown that the 
amount released increases with temperature. 
  The release study of acyclovir was done for the first two 
hours at an acidic pH using hydrochloric acid (pH 1.2) and 
then it was continued at an alkaline pH using phosphate 
buffer (pH 6.8). This was carried out for all the twelve 
formulations. The cumulative release at the end of the 2nd 
hour in the acidic pH and at the end of the 8th hour in 
alkaline pH were 29.5 mg and 191 mg for FY-1, 30.5 mg 
and 195 mg for FY-2, 30 mg and 193 mg for FY-3, 31.5 mg 
and 197.5 mg for FY-4, 55 mg and 395 mg for FY-5,  59 mg 
and 392 mg for FY-6, 61 mg and 396 mg for FY-7, 115 mg 
and 398 mg for FY-8. From FY-9 to FY-12, the cumulative 
release at 6th hour was also calculated, at the end of 2nd, 
6th and 8th hour, they were 118 mg, 156 mg and 776 mg 
for FY-9,  114 mg, 152 mg and 792 mg for FY-10, 124 mg, 
136 mg and 798 mg for FY-11. For FY-12 it was 122 mg at 
the end of the 2nd hour in the acidic pH and 792 mg in the 
alkaline pH. 
  The FT- IR of the microcapsules FY-1 to FY-12 was done. 
The spectra shows a strong absorption band at 1 716.78 for 
C=O group. An intense peak is observed at 1 635.1 cm
-1 for-
C=C-aromatic nuclei. Two strong absorption band was seen 
at 1 488.01 and 1 541.68 cm
-1 for 2 C=N, 8 C=N, stretching 
in ring. Absorption is seen at 1 308.91 for C-N stretching 
for primary amino group. Absorption is seen at 902.01 for 
5,6 alkene -CH=CH- group. Two strong absorption bands 
at 3 441.87, 3 480 cm
-1 and this confirms primary amino 
group. Absorption at 3 551 cm
-1, indicates presence of O-H 
(primary alcohol). Absorption is seen at 3 186.66 cm
-1 for 
C-H stretching at alkenes.  It was concluded that there was 
no interaction with acyclovir and bakers yeast based on the 
Table 1 
Preparation of acyloir loaded microcapsules using bakers yeast.
Sl No Sample No Temperature
Drug (mg)
in 5 mL 
buffer 
(pH5)
Yeast (g)
in 10 mL 
water
Water
 (mL)
Volume
taken for 
stirring 
(mL)
Stirring in 
rpm
Yield %
Entrapment efficiency
Amount of
drug released 
(mg)Absorbance
Entrapment
 (%)
1
   FY-1
25 ℃
200 0.4
20 35 2 000
69 0.759 90.35 191.0
   FY-5 400 0.8 76 0.770 91.66 395.0
   FY-9 800 1.6 94 0.773 92.02 776.0
2
   FY-2
30 ℃
200 0.4
20 35 2 000
71 0.765 91.07 195.0
   FY-6 400 0.8 75 0.779 92.73 392.0
   FY-10 800 1.6 93 0.784 93.33 792.0
3
   FY-3
35 ℃
200 0.4
20 35 2 000
68 0.782 93.09 193.0
   FY-7 400 0.8 74 0.790 94.04 396.0
   FY-11 800 1.6 91 0.799 95.11 798.0
4
   FY-4
40 ℃
200 0.4
20 35 2 000
70 0.812 96.66 197.5
   FY-8 400 0.8 77 0.820 97.61 398.0
   FY-12 800 1.6 92 0.810 96.42 792,0
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above given data. 
  The High Performance Liquid Chromatography (HPLC) was 
done for the pure drug acyclovir, FY-4(200 mg) and the peak 
found was 4 380 939, FY- 8(400 mg) the peak was 4 394 568, 
and FY-12 (800 mg) the peak was 4 326 804 and the content 
uniformity was ascertained (Table 2). 
  The Thermal analysis (DSC) was done for the standard (pure 
drug) acyclovir and sample FY-1, sample FY-3, sample FY-5 
and sample FY-7. For the standard (pure drug-acyclovir) two 
peaks were obtained at 168.54 ℃ and 278.99 ℃.  For sample 
FY- 1 a single peak was obtained at 263.70 ℃. Sample FY-3 
showed a single peak at 116.72 ℃, sample FY-5 showed two 
peaks at 160.49 ℃ and 260.77 ℃, Sample FY-7 gave one 
peak at 263.59 ℃. As per the standard (pure sample) the 
peak value is between 168.54 ℃ and 278.99 ℃. Except sample 
FY- 3 which showed a peak value of 116.72 ℃ all the other 
samples are within the range of the peak values of the standard 
acyclovir (Figure 6). 
4. Discussion
  The microcapsules of acyclovir was prepared using the 
drug, bakers yeast and water at specific ratio, at various 
temperatures and lyophilized to obtain the yield. The yield 
was maximum in the case of FY-9 (94%). The entrapment 
efficiency was found to be maximum in FY-8 (97.61). The 
SEM analysis revealed there was no burst on the surface 
and it was intact. The SEM of FY-3 was considered to be 
the best which was done at 10 毺m and 500 毺m. The 
particle size analysis showed size of 0-10 毺m in diameter 
was common in most groups except group FY-9, where most 
particles were found to be at 10-20 micrometer. 
  Entrapment efficiency for every 100 mg of the samples was 
done for all the twelve samples, FY-8 showed maximum 
entrapment of 97.61 mg. 
  The FTIR of the twelve samples showed no interaction 
between acyclovir and bakers yeast. The thermal analysis of 
standard (pure drug acyclovir) showed two peaks at 168.54 ℃ 
and 278.99 ℃, peaks of all samples were within the peak 
values of the standard one. 
  The dissolution study of the twelve samples showed the 
amount of release increased with temperature, and sample 
FY -8 had a cumulative drug release of 398 mg. 
  HPLC study showed FY-4, FY-8 and FY -12 were prepared 
in the form of suspension. It was found that the amount of 
acyclovir presented in 400 mg marketed sample was 397 
mg, for FY-4, FY-8 and FY-12 was 390.7 mg, 391.9 mg and 
386 mg, which are all above 95% and almost equal to the 
label claim of the marketed samples. So it has confirmed 
that sample FY- 8 is the best microencapsulated sample 
using acyclovir, yeast and water for micro encapsulation.
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Table 2
Formulation studies of acyclovir microcapsules by HPLC method.
Sl. No. Sample taken Peak area
Amount of acyclovir present in 
400 mg of sample (mg)
1 Standard drug 4 462 254 400.0 
2 Marketed sample 4 451 954 397.0 
3 Sample 4 4 380 939 390.7
4 Sample 8 4 394 568 391.9 
5 Sample 12 4 326 804 386.0 
